First Complement Inhibitor Wins Full Approval in IgA Nephropathy

The FDA fully approved iptacopan (Fabhalta), a complement inhibitor, to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of progression. Novartis announced the approval, marking the first complement inhibitor approved for this condition.